纳米材料是用于在生命系统中输送治疗剂的新兴事实。纳米技术通过实施不同类型的纳米技术应用来作为补充，例如纳米多孔结构、功能化纳米材料、量子点、碳纳米材料和聚合物纳米结构。该应用尚处于起步阶段，已在临床实践中实现了多项诊断和治疗。这篇综述传达了纳米材料在后基因组应用中的重要性，其中包括免疫传感器的设计、免疫测定和药物输送。从这个角度来看，基因组学是一种包含大型数据库的分子工具，可用于在药物递送过程中选择合适的分子抑制剂，例如药物、配体和抗体靶标。本研究确定了疾病分析和分类中基因和蛋白质的表达。该研究通过实验分析了疾病模型的设计。特别是，药物输送是治疗癌症的一个有利领域。已确定的药物进入不同的阶段试验（试验 I、II 和 III）。基因组信息为第一阶段试验提供了更多重要的实体，并有助于进一步推进其他试验，例如试验 II 和 III。在这种情况下，生物标志物通过监测独特的病理过程发挥着至关重要的作用。基因工程与重组 DNA 技术可用于开发基因工程疾病模型。在特定区域输送药物是使用纳米粒子实现的挑战性问题之一。因此，基因组学被认为是一种巨大的分子工具，可用于识别癌症治疗个性化医疗中的药物。版权所有 © 2023 Elsevier B.V. 保留所有权利。

Nanomaterials are emerging facts used to deliver therapeutic agents in living systems. Nanotechnology is used as a compliment by implementing different kinds of nanotechnological applications such as nano-porous structures, functionalized nanomaterials, quantum dots, carbon nanomaterials, and polymeric nanostructures. The applications are in the initial stage, which led to achieving several diagnoses and therapy in clinical practice. This review conveys the importance of nanomaterials in post-genomic employment, which includes the design of immunosensors, immune assays, and drug delivery. In this view, genomics is a molecular tool containing large databases that are useful in choosing an apt molecular inhibitor such as drug, ligand and antibody target in the drug delivery process. This study identifies the expression of genes and proteins in analysis and classification of diseases. Experimentally, the study analyses the design of a disease model. In particular, drug delivery is a boon area to treat cancer. The identified drugs enter different phase trails (Trails I, II, and III). The genomic information conveys more essential entities to the phase I trials and helps to move further for other trails such as trails-II and III. In such cases, the biomarkers play a crucial role by monitoring the unique pathological process. Genetic engineering with recombinant DNA techniques can be employed to develop genetically engineered disease models. Delivering drugs in a specific area is one of the challenging issues achieved using nanoparticles. Therefore, genomics is considered as a vast molecular tool to identify drugs in personalized medicine for cancer therapy.Copyright © 2023 Elsevier B.V. All rights reserved.